The pathogenicity of PSEN2 variants is tied to Aβ production and homology to PSEN1

被引:1
|
作者
Liu, Lei [1 ,2 ]
Schultz, Stephanie A. [2 ,3 ]
Saba, Adriana [1 ]
Yang, Hyun-Sik [1 ,2 ]
Li, Amy [1 ]
Selkoe, Dennis J. [1 ,2 ]
Chhatwal, Jasmeer P. [1 ,2 ,3 ]
机构
[1] Brigham & Womens Hosp, Dept Neurol, Boston, MA USA
[2] Harvard Med Sch, Boston, MA USA
[3] Massachusetts Gen Hosp, Dept Neurol, Boston, MA USA
关键词
amyloid beta; amyloid precursor protein; autosomal dominant Alzheimer's disease; familial Alzheimer's disease; gamma secretase; presenilin; FAMILIAL ALZHEIMERS-DISEASE; GAMMA-SECRETASE; PRESENILIN; MUTATIONS; PEPTIDES; MECHANISM; CLEAVAGE; DISTINCT; MICE;
D O I
10.1002/alz.14339
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
INTRODUCTION: Though recognized as a potential cause of autosomal dominant Alzheimer's disease, the pathogenicity of many PSEN2 variants remains uncertain. We compared amyloid beta (A beta) production across all missense PSEN2 variants in the AlzForum database and, when possible, to corresponding PSEN1 variants. METHODS: We expressed 74 PSEN2 variants, 21 of which had known, homologous PSEN1 pathogenic variants with the same amino acid substitution, in HEK293 cells lacking presenilin 1/2. A beta production was compared to age at symptom onset (AAO) and between PSEN1/2 homologs. RESULTS: A beta 42/40 and A beta 37/42 ratios correlated with AAO across all PSEN2 variants, strongly driven by the subset of PSEN2 variants with PSEN1 homologs. A beta production across PSEN1/2 homologs was highly correlated. PSEN2 AAO correlated with AAO in PSEN1 homologs but was an average of 18.3 years later. DISCUSSION: The existence of a PSEN1 homolog and patterns of A beta production are important considerations in assessing the pathogenicity of previously reported and new PSEN2 variants.
引用
收藏
页码:8867 / 8877
页数:11
相关论文
共 50 条
  • [21] Presence of a mutation in PSEN1 or PSEN2 gene is associated with an impaired brain endothelial cell phenotype in vitro
    Snehal Raut
    Ronak Patel
    Abraham J. Al-Ahmad
    Fluids and Barriers of the CNS, 18
  • [22] Amyloid-β1-43 cerebrospinal fluid levels and the interpretation of APP, PSEN1 and PSEN2 mutations
    Perrone, Federica
    Bjerke, Maria
    Hens, Elisabeth
    Sieben, Anne
    Timmers, Maarten
    De Roeck, Arne
    Vandenberghe, Rik
    Sleegers, Kristel
    Martin, Jean-Jacques
    De Deyn, Peter P.
    Engelborghs, Sebastiaan
    van der Zee, Julie
    Van Broeckhoven, Christine
    Cacace, Rita
    ALZHEIMERS RESEARCH & THERAPY, 2020, 12 (01)
  • [23] Orchestration of Genetic Alterations in PSEN1 and PSEN2 Genes in Development of Alzheimer's Disease through Computational Analysis
    Mir, Asif
    Kamran, Zainab
    Iqbal, Wajid
    GLOBAL MEDICAL GENETICS, 2024, 11 (01): : 1 - 12
  • [24] Distinct Clinical Characteristics of PSEN1 P.Cys263phe Carriers Compared with Other PSEN1, PSEN2 and APP Carriers in a Flanders-Belgian AD Cohort
    Hens, Elisabeth
    Van den Ende, Jenneke
    Engelborghs, Sebastiaan
    Vandenberghe, Rik
    De Deyn, Peter
    Cras, Patrick
    Van Broeckhoven, Christine
    NEUROLOGY, 2021, 96 (15)
  • [25] Novel presenilin 1 and 2 double knock-out cell line for in vitro validation of PSEN1 and PSEN2 mutations
    Pimenova, Anna A.
    Goate, Alison M.
    NEUROBIOLOGY OF DISEASE, 2020, 138
  • [26] Integrative multiomics reveals common endotypes across PSEN1, PSEN2, and APP mutations in familial Alzheimer's disease
    Valdes, Phoebe
    Caldwell, Andrew B.
    Liu, Qing
    Fitzgerald, Michael Q.
    Ramachandran, Srinivasan
    Karch, Celeste M.
    Galasko, Douglas R.
    Yuan, Shauna H.
    Wagner, Steven L.
    Subramaniam, Shankar
    ALZHEIMERS RESEARCH & THERAPY, 2025, 17 (01)
  • [27] Novel PSEN1 and PSEN2 Mutations Identified in Sporadic Early-onset Alzheimer Disease and Posterior Cortical Atrophy
    Li, Xu-Ying
    Cui, Yue
    Jing, Donglai
    Xie, Kexin
    Zhong, Xiaoling
    Kong, Yu
    Wang, Yuting
    Cha, Min
    Wang, Chaodong
    Wu, Liyong
    ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 2021, 35 (03): : 208 - 213
  • [28] The associations of APP, PSEN1, and PSEN2 genes with Alzheimer's disease: A large case-control study in Chinese population
    Xiao, Xuewen
    Liu, Hui
    Zhou, Lu
    Liu, Xixi
    Xu, Tianyan
    Zhu, Yuan
    Yang, Qijie
    Hao, Xiaoli
    Liu, Yingzi
    Zhang, Weiwei
    Zhou, Yafang
    Wang, Junling
    Li, Jinchen
    Jiao, Bin
    Shen, Lu
    Liao, Xinxin
    CNS NEUROSCIENCE & THERAPEUTICS, 2023, 29 (01) : 122 - 128
  • [29] APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases
    Lanoiselee, Helene-Marie
    Nicolas, Gael
    Wallon, David
    Rovelet-Lecrux, Anne
    Lacour, Morgane
    Rousseau, Stephane
    Richard, Anne -Claire
    Pasquier, Florence
    Rollin-Sillaire, Adeline
    Martinaudl, Olivier
    Quillard-Muraine, Muriel
    de la Sayette, Vincent
    Boutoleau-Bretonniere, Claire
    Etcharry-Bouyx, Frederique
    Chauvire, Valerie
    Sarazin, Marie
    le Berl, Isabelle
    Epelbaum, Stephane
    Jonveaux, Therese
    Rouaud, Olivier
    Ceccaldi, Mathieu
    Felician, Olivier
    Godefroy, Olivier
    Formaglio, Maite
    Croisile, Bernard
    Auriacombe, Sophie
    Chamard, Ludivine
    Vincent, Jean-Louis
    Sauvee, Mathilde
    Marelli-Tosi, Cecilia
    Gabelle, Audrey
    Ozsancak, Canan
    Pariente, Jeremie
    Paquet, Claire
    Hannequin, Didier
    Campion, Dominique
    PLOS MEDICINE, 2017, 14 (03)
  • [30] Lack of APOE Christchurch variant in five age of onset outliers with PSEN1, PSEN2 Alzheimer's disease and MAPT frontotemporal dementia
    Yu, Chang-En
    Chen, Sunny
    Jayadev, Suman
    Bird, Thomas
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2020, 418